$DERM Balance Sheet | Understand Stock

$DERM

$4.96 -$0.01 (0.2%) Close

$DERM Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q3 FY2023 As of Aug 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021
ASSETS
Current assets
Cash
Cash and cash equivalents
Accounts receivable, net of reserves
Inventory
Prepaid expenses and other current assets
Total current assets
Intangible assets, net
Operating lease right-of-use asset, net
Deferred tax assets
Other assets
Total assets

LIABILITIES AND STOCKHOLDERS' EQUITY
LIABILITIES
Current liabilities
Accounts payable
Due to related party
Accrued expenses
Accrued expenses, related party
Accrued interest
Income taxes payable
Line of credit
Deferred cash payment, net of discount
Installment payments - licenses, short-term
Term loan, short-term
Operating lease liability, short-term
Total current liabilities

Income tax payable
Note payable, related party
Term loan, long-term, net of discount
Installment payments - licenses, long-term
Derivative warrant liability
Convertible class A preferred stock settled note, short-term (net of debt discount of $1,923 as of September 30, 2021)
Operating lease liability, long-term
Total liabilities

Stockholders' equity
Common stock
Common stock
Common stock - Class A
Additional paid-in capital
Accumulated deficit
Total stockholders' equity
Total liabilities and stockholders' equity

Comments